Hematopoetic stem cell infusion ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 13 | 多発性硬化症／視神経脊髄炎 | 2 |
13. 多発性硬化症／視神経脊髄炎
臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02084121 (ClinicalTrials.gov) | March 2014 | 7/3/2014 | Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis (Compassionate Use) | Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis (Compassionate Use) | Metachromatic Leukodystrophy | Biological: Enriched Hematopoetic Stem Cell Infusion | Talaris Therapeutics Inc. | Duke University | No longer available | 3 Years | N/A | Male | United States | ||
| 2 | NCT00497952 (ClinicalTrials.gov) | July 2007 | 6/7/2007 | Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis | Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis | Multiple Sclerosis | Biological: hematopoetic stem cell infusion | Talaris Therapeutics Inc. | NULL | Active, not recruiting | 18 Years | 55 Years | All | 3 | Phase 1/Phase 2 | United States |